Nature Reviews Clinical Oncology

Nature Reviews Clinical Oncology

Springer Science and Business Media LLC

ISSN: 1759-4774 E-ISSN: 1759-4782 Q1
United Kingdom
English
Medicine
SJR: 28.076
H-Index: 259

Journal Metrics

Articles 199
Authors 661
Citations 0
H-Index 0

About this Journal

Nature Reviews' clinical content is written by internationally renowned clinical academics and researchers and targeted towards readers in the medical sciences, from postgraduate level upwards. While intended to be read by practicing doctors, researchers and academics within a specialty, we aim to make all our articles accessible to readers working in any medical discipline. In-depth Reviews present authoritative, up-to-date information on a topic, placing it in the context of a field's history and development. Topical discussion and opinions are proffered in Perspectives and News & Views articles, and in the Research Highlights section we filter primary research from a range of specialty and general medical journals.

199
Articles
661
Authors
2
Volumes
19
Issues
2025–2026
Year Range

Journal Analytics

Publication Trend

Articles per Volume

Author Growth

Monthly Publications (Last 12 Months)

Top Contributing Authors

1 Peter Sidaway
23 articles
2 Diana Romero
23 articles
3 David Killock
23 articles
4 Alireza Mansouri
3 articles
5 Ahmad Ozair
3 articles
6 Debarati Bhanja
3 articles
7 Hannah Wilding
3 articles
8 Nicholas Mikolajewicz
3 articles
9 Giuseppe Minniti
3 articles
10 Patrick Y. Wen
3 articles

Latest Articles

Ibrutinib improves overall survival in patients with mantle cell lymphoma

Peter Sidaway Jul 01, 2026 10.1038/s41571-026-01166-7

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA

Diana Romero Jul 01, 2026 10.1038/s41571-026-01169-4

Clinical implementation of multi-cancer early detection tests: can we find a path forward?

Ariadna Tibau, Aaron S. Kesselheim Jul 01, 2026 10.1038/s41571-026-01158-7

Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer

David Killock Jul 01, 2026 10.1038/s41571-026-01162-x

Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer

W. K. Jacky Lam, Brigette B. Y. Ma Jul 01, 2026 10.1038/s41571-026-01157-8

Synergistic integration of regional and systemic therapies in uveal melanoma

Shaheer A. Khan, Richard D. Carvajal Jul 01, 2026 10.1038/s41571-026-01155-w

The clinical landscape of HIF2α inhibitors in oncology

Eddy Saad, Marc Machaalani, David F. McDermott et al. Jul 01, 2026 10.1038/s41571-026-01145-y

Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?

Javier-David Benitez-Fuentes, Deme Karikios, Bishal Gyawali Jul 01, 2026 10.1038/s41571-026-01154-x

Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders

Alaa Ali, Metin Ozdemirli, Mark P. Hamilton et al. Jul 01, 2026 10.1038/s41571-026-01147-w

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions

Jan Philipp Bewersdorf, Alain Mina, Maximilian Stahl et al. Jul 01, 2026 10.1038/s41571-026-01141-2

Volumes & Issues